Navigation Links
Regeneron Pharmaceuticals Announces Proposed Offering of Convertible Senior Notes due 2016
Date:10/17/2011

ified by the words such as, but not limited to, "intend," "expect," "estimate," "anticipate," "believe," "plan," "should," "may," "could," "will," "continue," and words or phrases of similar meaning.  As the forward-looking statements are based on the Company's current expectations, the Company cannot guarantee any related future results, levels of activity, performance or achievements.  All forward-looking statements included in this press release are based on management's assessment of information available to the Company on the date hereof or thereof and are subject to certain risks, uncertainties and assumptions.  The forward-looking statements reflect the Company's position as of the date they were made and the Company undertakes no obligation to update any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.  Actual results may differ materially from those projected in such forward-looking statements for a number of reasons including, but not limited to, the following: our expectations regarding clinical trials, development timelines, future IND filings for new product candidates, and regulatory filings and submissions for any of our product candidates in clinical development; fluctuations in our operating results, in particular if EYLEA™ or any of our other late-stage product candidates is approved for marketing, and our revenues, market share, and/or market acceptance of EYLEA™ or such other products do not meet the expectations of investors or analysts; the possible success of any of our current or future product candidates; the determinations by regulatory and administrative governmental authorities which may delay or restrict our ability to continue to develop or commercialize our product and drug candidates; pricing or reimbursement actions or decisions by government authorities or insurers affecting the coverage or reimbursement of any of our product ca
'/>"/>
SOURCE Regeneron Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Regeneron Announces Appointment of Joseph J. LaRosa as Senior Vice President, General Counsel and Secretary
2. Regeneron Announces Review of Biologics License Application for EYLEA™ (aflibercept injection) Extended by Three Months by FDA
3. Regeneron Announces Presentation at the 29th Annual J.P. Morgan Healthcare Conference
4. Regeneron Announces Presentation at the 2010 Deutsche Bank BioFest
5. Regenerons Rilonacept Granted European Marketing Authorization for Treatment of Cryopyrin-Associated Periodic Syndromes (CAPS)
6. Regeneron Pharmaceuticals and BioMed Realty Trust Host Ribbon-Cutting Ceremony at the Landmark at Eastview
7. BioMed Realty Trust Expands Landmark Leases With Regeneron Pharmaceuticals
8. Pacira Pharmaceuticals, Inc. Announces EXPAREL™ Data to Be Presented at Upcoming Medical Meetings
9. Inspiration Biopharmaceuticals Announces Acceptance of European Marketing Authorization Application for IB1001 for the Treatment of Hemophilia B
10. Elevation Pharmaceuticals Presents Positive Phase 2a Results in COPD Patients at the European Respiratory Society Annual Congress
11. Keryx Biopharmaceuticals Announces Completion of Patient Enrollment in Zerenex™ (Ferric Citrate) Phase 3 Long-Term Study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/28/2015)... , July 28, 2015 /PRNewswire/ - Aeterna Zentaris ... announced that it has granted to German life ... the development and commercialization of biotechnology (collectively, the ... recombinant oral allogenic tumor vaccine technology (the "Technology"), ... prostate cancer which is ready to enter a ...
(Date:7/28/2015)... July 28, 2015  Faced with increasing challenges ... palliative rather than symptomatic, the global healthcare industry ... therapies capable of curing or significantly changing the ... to look towards regenerative medicine as a viable ... paradigm in human health with the potential to ...
(Date:7/27/2015)... EDMONTON , July 27, 2015 /PRNewswire/ - Quest ... pharmaceutical company developing and commercializing products for the treatment ... Quest announces that it has closed a $1,000,000 ... private placement of 16,666,667 units of the Company at ... comprised of one common share and one common share ...
(Date:7/27/2015)... ... July 27, 2015 , ... Brady (NYSE:BRC), a ... 3 Ways to GHS Labels . This video provides useful information on ... (GHS) by effectively labeling chemical containers. , “With the fourth and final deadline ...
Breaking Biology Technology:Aeterna Zentaris Grants Option to Develop and Commercialize Oral Allogenic Cancer Vaccine Technology 2Aeterna Zentaris Grants Option to Develop and Commercialize Oral Allogenic Cancer Vaccine Technology 3Stem Cell Therapy to Redefine Regenerative Medicine, says Frost & Sullivan 2Stem Cell Therapy to Redefine Regenerative Medicine, says Frost & Sullivan 3Stem Cell Therapy to Redefine Regenerative Medicine, says Frost & Sullivan 4Stem Cell Therapy to Redefine Regenerative Medicine, says Frost & Sullivan 5Quest PharmaTech Closes $1,000,000 Private Placement 2Brady Releases “3 Roads to GHS Labels” Video 2
... , , KNOXVILLE and OAK RIDGE, Tenn., ... Valley ( www.knoxvilleoakridge.com ) see the successful test of Boeing,s 787 ... Innovation Valley is home to Oak Ridge National Laboratory (ORNL), the ... forefront of applied carbon fiber research. , The potential ...
... CITY, Dec. 18 /PRNewswire-FirstCall/ - AEterna Zentaris Inc. (NASDAQ: ... biopharmaceutical company focused on oncology and endocrine therapy, today ... ( SNY) dated March 5, 2009 for the development, ... (BPH) for the U.S. market, following the Company,s announcement ...
... , LANSING, Mich., Dec. 18 Neogen Corporation (Nasdaq: ... second quarter of FY 2010, which ended Nov. 30, increased ... 3-for-2 stock split effective Dec. 15, net income in the ... year,s $0.17. Neogen,s second quarter net income of $4,610,000 set ...
Cached Biology Technology:Boeing Flight Boosts Carbon Fiber Hopes, Knoxville-Oak Ridge Innovation Valley Poised 2Boeing Flight Boosts Carbon Fiber Hopes, Knoxville-Oak Ridge Innovation Valley Poised 3AEterna Zentaris Announces Termination of Agreement with sanofi-aventis U.S. for the Development, Commercialization and Licensing of Cetrorelix in Benign Prostatic Hyperplasia 2Neogen Reports 18% Increase in Net Income 2Neogen Reports 18% Increase in Net Income 3Neogen Reports 18% Increase in Net Income 4Neogen Reports 18% Increase in Net Income 5Neogen Reports 18% Increase in Net Income 6Neogen Reports 18% Increase in Net Income 7
(Date:7/7/2015)... , June 30, 2015 ... has announced the addition of the "Capacitive ... offering. To this date, fingerprint sensing ... technology and fingerprint sensors are well developed. This ... sensing technology. The domain of capacitive ...
(Date:7/7/2015)... OXFORD, Conn. , July 7, 2015 NXT-ID, Inc. ... company focused on the growing mobile commerce market announces a revised ... airing this week. The commercial will air on CNBC in ... Los Angeles and San Francisco ... The commercial focuses on Wocket,s ability to replace all the ...
(Date:7/2/2015)... -- Research and Markets( http://www.researchandmarkets.com/research/jvft55/next_generation ) ... Biometrics Market by Application, Technology, Function & Geography - ... The next generation biometrics market is expected ... of 17.9% between 2015 and 2020 Travel ... Safran SA ( France ), ...
Breaking Biology News(10 mins):Worldwide Capacitive Fingerprint Sensors Patent Landscape Market Report 2015-2020 - Main IP Holders include Seiko Epson, AuthenTec, Sony and STMicroelectronics 2Wocket Smart Wallet Commercials Airing on CNBC to Showcase This Summer's Must- Have Tech Product 2Wocket Smart Wallet Commercials Airing on CNBC to Showcase This Summer's Must- Have Tech Product 3Next Generation Biometrics Market 2015 - Global Forecast to 2020 with Safran, NEC, 3M Cogent, Fujitsu & Suprema Dominating the $24 Billion Market 2Next Generation Biometrics Market 2015 - Global Forecast to 2020 with Safran, NEC, 3M Cogent, Fujitsu & Suprema Dominating the $24 Billion Market 3
... In our zest for cleanliness, have we permanently muddied ... from Arizona State University, in collaboration with federal partners,has ... Minnesota, finding widespread evidence of the presence of active ... and rivers. These products are a billion dollar ...
... species could soon follow, according to new research. Scientists have ... team has now carried out the first experiment to prove ... Society journal Biology Letters , the study shows how ... to become extinct. The University of Exeter team believes any ...
... the U.S. Department of Energy,s Ames Laboratory are helping ... tissue structures. The new method opens up new ... for biofuels research and crop genetics. "The ... Ames Laboratory faculty scientist heading up the project, funded ...
Cached Biology News:Antimicrobials from personal care products found in statewide survey of Minnesota's rivers and lakes 2Antimicrobials from personal care products found in statewide survey of Minnesota's rivers and lakes 3Antimicrobials from personal care products found in statewide survey of Minnesota's rivers and lakes 4Study proves that 1 extinction leads to another 2Finding new research frontiers in a single cell 2Finding new research frontiers in a single cell 3
... materials necessary for the isolation and preparation of ... Kit Components: Erythrocyte ... containing 220 mL of buffered ammonium chloride. (NH ... No. 5113) One bottle containing 220 mL of ...
... culture systems provide an integrated ... for staining and imaging. Each ... preassembled with standard optical-quality coverslips ... entire system is provided sterile ...
ANTI NO-TRYPTOPHAN CONJUGATE...
... The Zero Background/Kan Cloning ... with kanamycin resistance for selection ... vector utilizes positive selection to ... contains all of the reagents ...
Biology Products: